Psychotherapy

Transcranial magnetic stimulation can treat depression. Developing research suggests it could also help autism, ADHD and OCD

Retrieved on: 
Monday, August 28, 2023
People, Technology, Maintenance, Depression, Tic disorder, OCD, Electroconvulsive therapy, ADHD, Psychotherapy, Brain, Research, Attention, COVID, Scalp, Disorder, Medicare, Addiction, Attention deficit hyperactivity disorder, Dementia, Patient, Smoke, Spectrum, Transcranial magnetic stimulation, Adolescence, Headache, Recurrence, Chronic pain, Hospital, Dietary supplement, Pharmaceutical industry, Nursing, Medical imaging, Vaccine

A new therapeutic option, especially for depression, transcranial magnetic stimulation, is slowly helping to address some of these considerable unmet needs in our community.

Key Points: 
  • A new therapeutic option, especially for depression, transcranial magnetic stimulation, is slowly helping to address some of these considerable unmet needs in our community.
  • Read more:
    Treating mental illness with electricity marries old ideas with modern tech and understanding of the brain – podcast

How does it work and who’s getting it now?

    • Transcranial magnetic stimulation involves the application of a series of magnetic pulses through a coil placed on the scalp.
    • They may include scalp discomfort, headache, tingling or facial twitching, and feeling lightheaded for a short time after a treatment session.
    • There is consistent evidence for the effectiveness of transcranial magnetic stimulation treatment for acute episodes of depression.
    • Studies both locally and overseas have started to show more efficient delivery and very rapid clinical benefits with these new treatment regimes.

What about for other conditions?

    • Alongside the clinical rollout of transcranial magnetic stimulation for depression, research is increasingly demonstrating its potential value in other conditions.
    • The treatment is showing promise for addiction disorders, including the development of an approach using transcranial magnetic stimulation to help patients stop smoking.
    • As clinical need escalates, early research is also exploring whether transcranial magnetic stimulation might alleviate symptoms of attention deficit hyperactivity disorder (ADHD).
    • Read more:
      People with obsessive-compulsive disorder have an imbalance of brain chemicals – our discovery could mean a treatment breakthrough

Do the effects last?

    • So far, the quality of the evidence on the persistence of effects and the need for maintenance treatment with the use of transcranial magnetic stimulation in depression is patchy.
    • Preliminary studies suggest maintenance treatment is effective, but there there have been insufficient high-quality studies to convince Medicare to provide a subsidy for it.
    • Medicare funding also does not fund the provision of transcranial magnetic stimulation for patients who experience the return of their depression on more than one occasion.

University of Miami Department of Psychiatry and Behavioral Sciences Announces Open Registration for Latest Continuing Education Course

Retrieved on: 
Friday, August 25, 2023
Psychology, Psychopharmacology, Abstract, Happiness, University, Beth Israel Deaconess Medical Center, Q&A, John Singleton Copley, Lecture, Cambridge Health Alliance, Division, Research, Emotion, Multimedia, Parent, Continuing medical education, Mindfulness, Bentham Science Publishers, Compassion, Harvard Medical School, Journal of Child and Adolescent Psychopharmacology, Journal, Behavioural sciences, Meditation, LICSW, Patient, Neuroscience, Psychiatry, Miele, Faculty, Adolescence, Nursing, Psychotherapy, Child

MIAMI, Aug. 25, 2023 /PRNewswire-PRWeb/ -- The University of Miami Leonard M. Miller School of Medicine's Department of Psychiatry and Behavioral Sciences is thrilled to announce registration is now open for their latest psychiatry continuing education course, Meditation for Peak Performance and Enduring Happiness. This evidence-based course integrates the latest western scientific research on peak performance and positive psychology with ancient insights from the great contemplative traditions of the east. While western psychotherapeutics traditionally emphasize alleviating painful emotional states, this course focuses instead on practical tools to cultivate positive emotions and psychological resources to support mental and physical health in patients.

Key Points: 
  • MIAMI, Aug. 25, 2023 /PRNewswire-PRWeb/ -- The University of Miami Leonard M. Miller School of Medicine's Department of Psychiatry and Behavioral Sciences is thrilled to announce registration is now open for their latest psychiatry continuing education course, Meditation for Peak Performance and Enduring Happiness.
  • As the first meditation continuing education course hosted by the Department of Psychiatry and Behavioral Sciences, director of Continuing Medical Education, Kim Miele, has utilized her past twenty-five years of success in continuing education to elevate Miami's course offerings.
  • For more information about the University of Miami Department of Psychiatry and Behavioral Sciences please visit https://med.miami.edu/departments/psychiatry .
  • Kim Miele - Director of Continuing Medical Education, University of Miami Department of Psychiatry and Behavioral Science, 1 941-932-2671, [email protected] , https://umiami-cme.org/
    View original content to download multimedia: https://www.prweb.com/releases/university-of-miami-department-of-psychia...

Oxford Treatment Center at Forefront of Equine-Assisted Therapy Research for Addiction

Retrieved on: 
Monday, August 14, 2023
Partnership, EAP, University, Mississippi State University, Gait, Katie, Anxiety, Perception, Equine-assisted therapy, Respiration, Psychotherapy, Research, EAL, Judgement, Shame, Walking, Patient, Heart rate, Mental health, Environment, CCTP, Regulation, Pharmaceutical industry, Nursing

After obtaining her doctorate, Dr. Holtcamp continued and expanded her research in equine-assisted therapy.

Key Points: 
  • After obtaining her doctorate, Dr. Holtcamp continued and expanded her research in equine-assisted therapy.
  • She and her research group, Dogwood Wellness Group, with the cooperation of Mississippi State University and Oxford Treatment Center, have now spent more than five years conducting quantitative research on the efficacy of equine-assisted therapy.
  • “My ultimate goal is to change the perception many have of this form of therapy, because like the stigma associated with addiction, it is unwarranted.
  • When done correctly, this treatment method is effective, and with the help of Oxford, we will continue to collect the research to back that up.”

Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression

Retrieved on: 
Monday, August 14, 2023
Blood pressure, Arm, Depression, Czech Republic, Incidence, Dissociative, Patient, Grammatical mood, Psychiatry, Ketamine, Heart rate, TRD, Safety, Pharmaceutical industry, Psychotherapy

MUNICH, Germany, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Ketabon, a joint venture between HMNC Brain Health and Develco Pharma, announced today top-line results from its Phase 2 KET01-02 Ketabon study with lead asset KET01. KET01 is an oral adjunctive treatment featuring a prolonged-release formulation of ketamine and is being studied in patients with treatment-resistant depression (TRD).

Key Points: 
  • KET01 is an oral adjunctive treatment featuring a prolonged-release formulation of ketamine and is being studied in patients with treatment-resistant depression (TRD).
  • KET01, at a 240mg/day dose, demonstrated rapidly occurring, and clinically relevant improvements in depressive severity with statistical significance versus placebo on Day 4 and Day 7.
  • The improvements from baseline were sustained while on active treatment until Day 21, and also after the 4-week follow-up period.
  • “KET01 offers rapid improvement of depressive symptoms while the occurrence of dissociative events interestingly seems to be lower than in currently used ketamine-based treatments.

Former Gaming Entrepreneur Now Holding Mental Health to a Higher Standard with Launch of Glimmer

Retrieved on: 
Tuesday, August 15, 2023
Yoga, Würzweiler, IPO, University, Child and adolescent psychiatry, Ego-state therapy, Spirituality, Domestic violence, Neurofeedback, Saint George, Quality of life, Psychotherapy, Case Western Reserve University, Private practice, COVID, The Couch, Adolescence, Mindfulness, Bentham Science Publishers, Parenting, Social, Social work, Eye movement desensitization and reprocessing, Student, Trust, Patient, Psychiatry, St. George's University, Virtual reality, EMDR, MSW, Trauma, Mental health, Sensorimotor psychotherapy, Pneumonia, Safety, Nursing, Judaism, Child, Glimmer

TORONTO, Aug. 15, 2023 /PRNewswire-PRWeb/ -- Today, Glimmer announced its guided therapy platform to connect patients with a higher standard of mental health care. After 10 years taking a gaming startup to IPO, founder Menashe Kestenbaum is applying similar gamification principles to the management of mental health care using technology, data, and a holistic treatment approach in order to improve the experience and quality of therapy in a measurable way.

Key Points: 
  • Today, Glimmer announced its guided therapy platform to connect patients with a higher standard of mental health care.
  • TORONTO, Aug. 15, 2023 /PRNewswire-PRWeb/ -- Today, Glimmer announced its guided therapy platform to connect patients with a higher standard of mental health care.
  • Glimmer holds therapy to a higher standard by using data to accurately match therapists with clients based on compatibility and trust.
  • Additionally, Dr. Biberfeld is a supervisor for Torah Umesora's mental health training program for teachers and principals.

University of Phoenix College of Doctoral Studies releases white paper exploring burnout as a cause for job dissatisfaction

Retrieved on: 
Saturday, August 12, 2023
Professional Services, Education, Business, Other Professional Services, Human Resources, University, Training, Burnout, Health administration, Emergency medicine, University of Texas System, DHA, Causality, Child protective services, Workplace, Teaching, McGovern Medical School, Marriage, Psychotherapy, MBA, Job satisfaction, Great Lakes University of Kisumu, Argosy University, University of Phoenix, Organization, Interface (computing), Business administration, Student, City, Tuberculosis, Doctor, Child, Barstow Community College, Phoenix College, University of Texas Health Science Center at Houston, Master of Business Administration, Health, Mental health, Nursing

University of Phoenix College of Doctoral Studies has released a new white paper, “Burnout as a Cause for Job Dissatisfaction,” a collaboration between authors Christa Banton, Ed.D., fellow in the University’s Center for Workplace Diversity and Inclusion Research (CWDIR) and Jose Garza, DHA, MBA, fellow, CWDIR.

Key Points: 
  • University of Phoenix College of Doctoral Studies has released a new white paper, “Burnout as a Cause for Job Dissatisfaction,” a collaboration between authors Christa Banton, Ed.D., fellow in the University’s Center for Workplace Diversity and Inclusion Research (CWDIR) and Jose Garza, DHA, MBA, fellow, CWDIR.
  • The white paper proposes that to address burnout, it is imperative to understand the facets of job satisfaction and create solutions to improve job satisfaction and overall burnout.
  • “Understanding the consequences of job dissatisfaction and tracking an organization’s level of work-life balance can provide an early indicator of intervention to improve job satisfaction, retention rates, and decrease overall burnout,” states Banton.
  • Garza completed his Doctorate in Health Administration with University of Phoenix and a Master of Business Administration with a concentration in healthcare management from Our Lady of the Lake University.

Fluence Announces Graduation of First Cohort of Students in Certificate in Psilocybin-Assisted Therapy

Retrieved on: 
Thursday, August 10, 2023
Psilocybin, LCSW, NCC, Integration, Curriculum, Psychotherapy, Oregon Higher Education Coordinating Commission, History, Doctor of Philosophy, Oregon Health Authority, Science, Social, Oregon Health and Science University Center for Women's Health, Student, Physician, Nursing, 2020 Oregon Ballot Measure 109, Knowledge, Addiction, Trauma, Mental health, LPC, OPS, Counselor, Satellite navigation device, Radiant exposure

PORTLAND, Ore., Aug. 10, 2023 /PRNewswire-PRWeb/ -- Fluence, a leading psychedelic therapy training organization, today announced the graduation of the first cohort of students in its Certificate in Psilocybin-Assisted Therapy. The 9-month training program, which launched in November 2022, provides students with the knowledge and skills they need to provide psilocybin sessions under Oregon's Measure 109.

Key Points: 
  • PORTLAND, Ore., Aug. 10, 2023 /PRNewswire-PRWeb/ -- Fluence , a leading psychedelic therapy training organization, today announced the graduation of the first cohort of students in its Certificate in Psilocybin-Assisted Therapy .
  • The 9-month training program, which launched in November 2022, provides students with the knowledge and skills they need to provide psilocybin sessions under Oregon's Measure 109.
  • The program is grounded in Fluence's Psychedelic Harm Reduction and Integration (PHRI) approach to psychedelic-assisted therapy and integration.
  • It is designed and taught by leading experts with psilocybin-assisted therapy experience in clinical research settings.

Ozempic is in the spotlight but it's just the latest in a long and strange history of weight-loss drugs

Retrieved on: 
Tuesday, August 8, 2023
Exercise, Injection, Seizure, Amgen, Letter, Endocrinology, Human, Food, Obesity, Industry, Diet, US Food Sovereignty Alliance, Diabetes, Ephedra, Leptin, Stroke, Phentermine, Splenic infarction, Hope, Psychotherapy, Research, Appetite, History, Diarrhea, Due, Sale, Movement, Hormone, Science, Athlete, US, Dietary supplement, Patient, Time, Poisoning, Amphetamine, Novo Nordisk, Overweight, Hypothalamus, Pleasure, Fenfluramine, Nausea, Mouse, Growth, Knowledge, Health, Death, Safety, Social environment, Social media, Cosmetics, Canning, Birth control, Pharmaceutical industry, Drug, Nightclub, Semaglutide

That’s been the holy grail of weight-loss ever since 19th century English undertaker and weight-loss celebrity William Banting’s 1863 Letter on Corpulence spruiked his “miraculous” method of slimming down.

Key Points: 
  • That’s been the holy grail of weight-loss ever since 19th century English undertaker and weight-loss celebrity William Banting’s 1863 Letter on Corpulence spruiked his “miraculous” method of slimming down.
  • Since then, humans have tried many things – diet, exercise, psychotherapy, surgery – to lose weight.
  • But time and again we return to the promise of a weight-loss drug, whether it’s a pill, injection, or tonic.

Ozempic is a recent arrival

    • Ozempic and its sister drug Wegovy, both manufactured by Novo Nordisk, are the latest offerings in a long history of drug treatments for people who are overweight.
    • This has helped drive a shortage of Ozempic for diabetes treatment.

From ‘gland treatment’ to amphetamines

    • For example, organotherapy (gland treatment) was hugely popular in the 1920s to 1940s.
    • Doctors prescribed overweight people extracts of animal glands – either eaten raw or dried in pill form or injected – to treat their supposedly “sluggish glands”.
    • Amphetamines were first used as a nasal decongestant in the 1930s, but quickly found a market for weight-loss.
    • Amphetamines too, fell from treatment use in the 1970s with Nixon’s “war on drugs” and recognition they were addictive.

Another decade, another drug

    • For example, the popular diet drug of the 1980s and 90s was fen-phen, which contained appetite suppressants fenfluramine and phentermine.
    • And as history recognises, multiple complexities can combine to push a drug into popularity or damn it to history’s rubbish bin.
    • One noticeable contrast with past diet drug experiences is that now, many people are happy to talk about using Ozempic.
    • It seems to be increasingly socially acceptable to use a drug to achieve weight-loss for primarily aesthetic reasons.

Our enduring search for weight-loss drugs

    • Ozempic is predicted to earn Novo Nordisk US$12.5 billion this year alone, but it’s not just industry interests stoking this enduring desire for weight-loss drugs.
    • Patients on an endless cycle of dieting and exercise want something more convenient, with a more certain outcome.
    • It is no wonder demand for weight-loss drugs continues to soar.

Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening

Retrieved on: 
Tuesday, August 8, 2023
Depression, Q3, Royal Australian and New Zealand College of Psychiatrists, Quality of life, ASX, Diagnosis, PAT, PTSD, Nursing, Pharmaceutical industry, Clarion, Psychotherapy

MELBOURNE, Australia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that its subsidiary, Clarion Clinics Group Pty Ltd, is now accepting direct registration of interest in treatment from potential clients via its website at clarionclinics.com ahead of its planned Q3 opening.

Key Points: 
  • Incannex subsidiary, Clarion Clinics Group Pty Ltd (Clarion) begins accepting registrations of interest in its psychedelic-assisted therapy (PAT) treatments ahead of planned Q3 opening.
  • If accepted for treatment, clients will be treated for nine-months at a Clarion Clinic.
  • People who have an interest in treatment from Clarion can now register and request further information on the Clarion website.
  • At Clarion Clinics, our aim is to achieve the best outcomes possible using psychedelic therapies, through tailored and extended protocols and a brilliant team,” Dr. Paul Liknaitzky said.

American Psychedelic Practitioners Association and BrainFutures Publish First Professional Practice Guidelines for Psychedelic-Assisted Therapy

Retrieved on: 
Tuesday, August 8, 2023
Columbia University, Prevalence, National Institute of Mental Health, Professional, Mental health, DSM-IV codes, PTSD, Psychotherapy, Research, APPA, PMHNP, Assistant, MS, CDC, MD, UC, Patient, Post-traumatic stress disorder, Guideline, RET, Ethics, Ageing, FDA, MDMA, Safety, Nursing, Medical device

These guidelines aim to set a benchmark for practitioners in this emerging clinical field as informed by existing clinical research and expert consensus.

Key Points: 
  • These guidelines aim to set a benchmark for practitioners in this emerging clinical field as informed by existing clinical research and expert consensus.
  • Recognizing the need for guidelines to set high standards and further legitimize the burgeoning psychedelic-assisted therapy space, a working group of experts from multiple disciplines within the field came together to write the professional practice guidelines.
  • "As the field of psychedelic-assisted therapy continues to gain momentum, the release of the Professional Practice Guidelines marks a crucial turning point.
  • a member of the working group to develop the professional practice guidelines and a psychiatrist and Assistant Professor at Columbia University.